FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149931581> ?p ?o ?g. }

• W2149931581 endingPage "1235" @default.
• W2149931581 startingPage "1235" @default.
• W2149931581 abstract "Please allow me to clarify the terminology used to describe the intra-articular hyaluronan (IAHA) class of osteoarthritis (OA) treatments, in the excellent evidence update reported by Zhang et al. (OARSI recommendations for the management of hip and knee osteoarthritis part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis and Cartilage, February 17, 2010; 18(4); 473–99). In Table IV, the authors report a lower risk of local reactions for “IAHA” compared to “IA high molecular HA (hylan)”. This incorrectly suggests that the risk reported from the hylan G-F 20 trials is representative of all high molecular weight HA formulations. This is not the case, as HA and hylan are chemically distinct entities. Hylan is a generic term used to describe a class of HA derivatives chemically modified via their hydroxyl groups1Balazs E.A. Leshchiner E. Larsen N.E. Band P. Hyaluronan biomaterials: medical applications.in: Wise D.L. Handbook of Biomaterials and Applications. Marcel Dekker Inc., New York1995: 2719-2741Google Scholar. The hylan formulation tested in the reviewed trials, hylan G-F 20, contains both hylan A, a soluble high molecular weight derivative of HA, and hylan B, a crosslinked HA derivative that is a water insoluble hydrogel. This distinction between hylan and high molecular weight HA formulations is important, to avoid suggesting that the clinical profile described for hylan G-F 20 applies in a general way to all high molecular weight HA formulations. It is also worthwhile to note that all HA derivatives should not be expected to have the same clinical profile as hylan G-F 20. HA derivatives can be synthesized using different chemical methods, and formulated as different physical forms (e.g., solutions, solid hydrogels or gel–fluid mixtures). The safety and effectiveness of each derivative formulation should be evaluated for its intended use. The author was formerly an employee of Biomatrix, where the hylan G-F 20 formulation mentioned in the letter and publication was developed, and is currently a consultant to Smith-Nephew, a marketer and developer of IAHA products. Response from authors: ‘OARSI update on the evidence for osteoarthritis therapies’Osteoarthritis and CartilageVol. 18Issue 9PreviewWe appreciate Dr Philip Band’s letter in response to our recent publication OARSI recommendations for the management of hip and knee osteoarthritis Part III: changes in evidence following systematic cumulative update of research published through January 2009 (Osteoarthritis & Cartilage 2010; 18: 476–499). The meta-analysis (Reichenberg et al. Arthritis Rheum (Arthritis Care and Research) 2007; 57: 1410–1418) reported in Table IV showed that treatment with IA hylan G-F 20 (Synvisc) was associated with an increased relative risk of flares of joint pain (RR 2.04; 95% CI 1.18, 3.53; I2=0%) compared with IA avian hyaluronans (Hyalgan and Orthovisc), or the bacterial hyaluronan (Ostentil). Full-Text PDF Open Archive" @default.
• W2149931581 created "2016-06-24" @default.
• W2149931581 creator A5003684140 @default.
• W2149931581 date "2010-09-01" @default.
• W2149931581 modified "2023-10-18" @default.
• W2149931581 title "OARSI update on the evidence for osteoarthritis therapies: comment on the nomenclature used for intra-articular hyaluronan" @default.
• W2149931581 doi "https://doi.org/10.1016/j.joca.2010.03.019" @default.
• W2149931581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20633681" @default.
• W2149931581 hasPublicationYear "2010" @default.
• W2149931581 type Work @default.
• W2149931581 sameAs 2149931581 @default.
• W2149931581 citedByCount "1" @default.
• W2149931581 crossrefType "journal-article" @default.
• W2149931581 hasAuthorship W2149931581A5003684140 @default.
• W2149931581 hasBestOaLocation W21499315811 @default.
• W2149931581 hasConcept C142724271 @default.
• W2149931581 hasConcept C185592680 @default.
• W2149931581 hasConcept C204787440 @default.
• W2149931581 hasConcept C2776164576 @default.
• W2149931581 hasConcept C3020332539 @default.
• W2149931581 hasConcept C71924100 @default.
• W2149931581 hasConceptScore W2149931581C142724271 @default.
• W2149931581 hasConceptScore W2149931581C185592680 @default.
• W2149931581 hasConceptScore W2149931581C204787440 @default.
• W2149931581 hasConceptScore W2149931581C2776164576 @default.
• W2149931581 hasConceptScore W2149931581C3020332539 @default.
• W2149931581 hasConceptScore W2149931581C71924100 @default.
• W2149931581 hasIssue "9" @default.
• W2149931581 hasLocation W21499315811 @default.
• W2149931581 hasLocation W21499315812 @default.
• W2149931581 hasOpenAccess W2149931581 @default.
• W2149931581 hasPrimaryLocation W21499315811 @default.
• W2149931581 hasRelatedWork W1135326970 @default.
• W2149931581 hasRelatedWork W1979837964 @default.
• W2149931581 hasRelatedWork W2137188394 @default.
• W2149931581 hasRelatedWork W2170651748 @default.
• W2149931581 hasRelatedWork W2349510636 @default.
• W2149931581 hasRelatedWork W2366500498 @default.
• W2149931581 hasRelatedWork W2618557179 @default.
• W2149931581 hasRelatedWork W2748952813 @default.
• W2149931581 hasRelatedWork W2899084033 @default.
• W2149931581 hasRelatedWork W3197358415 @default.
• W2149931581 hasVolume "18" @default.
• W2149931581 isParatext "false" @default.
• W2149931581 isRetracted "false" @default.
• W2149931581 magId "2149931581" @default.
• W2149931581 workType "article" @default.